Five months after receiving an FDA rejection and laying off most of its staff, struggling cancer biotech Spectrum Pharmaceuticals is getting acquired.
Five months after receiving an FDA rejection and laying off most of its staff, struggling cancer biotech Spectrum Pharmaceuticals is getting acquired.
